Naseema Gangat, MBBS

Naseema Gangat, MBBS, discusses the JAK inhibitor ruxolitinib as the standard of care for the treatment of patients with myelofibrosis.

Naseema Gangat, MBBS, discusses the potential use of ruxolitinib and ropeginterferon alfa-2b-njft to reduce JAK2 allele burden in polycythemia vera.

Panelists discuss key accomplishments in the myeloproliferative neoplasm (MPN) space, highlighting pivotal developments that have shaped clinical practice, and share their excitement for 2025, including areas primed for significant progress and goals for the coming year.

Panelists discuss noteworthy updates in myelofibrosis (MF) from ASH 2024, share their views on the future of MF treatment, offer clinical pearls for community oncologists, and highlight emerging pathways and targets they are excited about for MF management.

Panelists discuss studies aimed at combating dose-dependent anemia as a consequence of Janus kinase inhibitors (JAKi) treatment and share their thoughts on potential strategies to address this challenge.

Panelists discuss the types of questions that real-world (RW) data can answer in comparison to with clinical trial data, and how it they can complement clinical findings in treatment decision-making.

Panelists discuss data from the FREEDOM2 trial and its sub-analysis on low platelet count with fedratinib (FEDR), as well as the pooled analysis of the COMFORT-I/-II trials on ruxolitinib (RUX) for myelofibrosis.

Panelists discuss how they select personalized therapy for patients with myelofibrosis (MF) based on current data, considering factors such as disease characteristics and patient-specific factors.

Panelists discuss their overall treatment goals for myelofibrosis (MF), the role of transplant within their practice, and the benefits and challenges associated with transplantation, as well as how they determine which patients are best suited for this approach.

Panelists discuss myelofibrosis (MF) and its diagnostic workup, including how patients with primary MF present, the criteria required for diagnosis, and any additional biomarkers or criteria examined in practice.

Panelists discuss noteworthy updates in polycythemia vera (PV) from ASH 2024, explore the future of PV treatment, highlight the greatest unmet needs, and discuss how ongoing investigational therapies aim to address these gaps. They also share clinical pearls for community oncologists in managing PV.

Panelists discuss monitoring parameters when treating patients with polycythemia vera (PV), including what to assess, typical outcomes, and when treatment should be switched due to ineffectiveness. Dr Kuykendall to Dr Gangat: Panelists explore the risk of PV progression/transformation, risk factors for progression, and how the data influence patient care and treatment choices in practice.

Panelists discuss real-world treatment patterns for ropeginterferon alfa-2b (Ropeg alfa-2b) in the management of polycythemia vera (PV).

Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).

Panelists discuss the safety profiles of therapies for polycythemia vera (PV) and the safety considerations they take into account when determining which patients are best suited for these treatments.

Panelists discuss additional data supporting the use of alternative agents and treatment pathways for polycythemia vera (PV), including the role of ropeginterferon alfa-2b (Ropeg alfa-2b) based on findings from the PROUD-PV /CONTINUATION-PV studies.

Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.

Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.

Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.